Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

BACKGROUND: Protease inhibitors (PIs) to treat hepatitis C (HCV) virus infection have been approved and others are under development. RESULTS: The aims of this study were to illustrate natural polymorphisms in the HCV protease and measure the frequency of PI resistance mutations in different HCV gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Paolucci, Stefania, Fiorina, Loretta, Piralla, Antonio, Gulminetti, Roberto, Novati, Stefano, Barbarini, Giorgio, Sacchi, Paolo, Gatti, Marta, Dossena, Luca, Baldanti, Fausto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493344/
https://www.ncbi.nlm.nih.gov/pubmed/23095680
http://dx.doi.org/10.1186/1743-422X-9-245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493344/
https://www.ncbi.nlm.nih.gov/pubmed/23095680
http://dx.doi.org/10.1186/1743-422X-9-245

Ejemplares similares